 |
| Over 70 Neuroscience Executives Speaking - Register Today |
|
|
|
|
|
Inside This Issue: Blood Brain Barrier
Top News Alerts: Product Updates, Deals & Financings
Conference in Review: 10th Antiepileptic Drugs Conference and Pipeline Update
Featured Company: AngioChem
Subscribe now to access over 40 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Financial Crisis Reshapes Neurotech Industry
Amarin (AMRN) rose 86% after the EMEA accepted a marketing application for AMR101 in Huntington’s. Amarin announced in 2007 that the results of a Phase III study did not show significance at six months, however, there was a significant treatment effect at 12 months in the 192 patients who completed a six month open label extension. The FDA has said it will require an additional trial and the company is out-licensing this and its other CNS programs. Xenoport (XNPT) was down 29% after their formulation for neuropathic pain failed to show efficacy due to a high placebo response (see story, page 7). Its competitor Avanir (AVNR), developing Zenvia for neuropathic pain, was up 67%. Avanir announced that it completed additional pre-clinical and clinical studies demonstrating cardiac safety for the new lower dose formulation of Zenvia which will be submitted in the complete response to the approvable letter for pseudobulbar affect. Targacept (TRGT) rose after announcing a new exploratory trial of their neuronal nicotinic agonist TC-5214 in resistant hypertension....
Emerging Strategies to Cross the Blood Brain Barrier
The blood brain barrier (BBB) was discovered in the early years of the twentieth century by bacteriologist Paul Ehrlich and his student Edwin Goldmann. The men noticed that dyes injected in the extracellular fluid would not stain the central nervous system, whereas dyes injected in the cerebrospinal fluid would not stain the rest of the body. The experiments demonstrated a compartmentalization in the extracellular fluid space that was hitherto unknown. This article outlines emerging strategies and technologies being used to get compounds across the BBB from companies like: Advanced Neuromodulation Systems, AngioChem, ArmaGen Technologies, BrainsGate, CCL Pharma, Ceregene, Codman, InSet Technologies, Medgenesis, Medtronic, NanoDel, Nanovector, Neurologix, Neurotech S/A, NsGene, Palyon, Raptor, StemCells Inc., Sierra Neuropharmaceuticals, toBBB, and Xigen
With Proof of Principle Results in Hand, AngioChem Seeks New Funding and Partnerships
AngioChem Inc. is a small company based in Montreal, Quebec with 22 employees. Its goal is to treat brain diseases by producing drugs that can cross the blood brain barrier easily. The company has developed a platform technology, called EPiC, or Engineered Peptide Compounds that readily cross the BBB by binding to the receptor for lipoprotein receptor-related protein (LRP). The technology was developed by AngioChem’s scientific founder Dr. Richard Beliveau, a professor at the Universite de Quebec a Montreal. NeuroInsights spoke with Dr. Jean-Paul Castaigne, President and CEO, who joined the company in September 2006. Prior to joining AngioChem, Dr. Castaigne was...
Companies Covered In This Issue Include: Accera, Acorda, Addrenex, Advanced Neuromodulation Systems, Alkermes, Alseres, Amarin, Ambrx, Anavex, AngioChem, Arena, ArmaGen Technologies, Avanir, Banyan, Bial, BiolineRX, BioCortech, BioMS Medical, BMS, BrainsGate, Cannasat, CCL Pharma, Cephalon, Ceregene, Codman, Cortex, Cytox, Eisai, Envoy, Icagen, InKano, InSet Technologies, Intelgenx, Izumi, Jazz Pharmaceuticals, KeyNeurotek, Lundbeck, Marinus, Medgenesis, Medivation, Medtronic, Merck, Merz, NanoDel, Nanovector, Neurologix, Neuralieve, Neuroscience Pharmaceuticals, Neurotech S/A, Neuropace, NsGene, Novartis, Orexigen, OrthoMcNeil, Paion, Palyon, Posit Science, Photothera, Pfizer, Psylin, Raptor, Repligen, Sanofi, Shire, Sirion Therapeutics, Saturis, SK Life Sciences, Somaxon, Sierra Neuropharmaceuticals, StemCells Inc., Supernus, Teva, toBBB, Transyme, UCB, Valeant, Xenoport, Xigen and more...
Subscribe Now:
|
|
